Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Pekka Raatikainen,
Dr. Botto started the session by presenting data on the burden of AF and the risk of stroke. He emphasized the importance of the detection of silent AF as the risk of stroke is similar among patients with asymptomatic and symptomatic AF. The problematic patient groups are those with short episodes of AF. These can be detected only by using implantable devices which monitor the heart rhythm continuously.
According to Prof. Lip, the recently developed CHA2DS2VASc and HAS-BLED score provide more accurate means for assessment of the risk of stroke and bleeding than the CHADS2 and the previous bleeding risk scores, respectively. In addition, he emphasized that aspirin is neither effective nor safe in management of patients with AF.
As a natural continuation to the previous presentations, Prof. Neuzil described the new pharmacological and interventional stroke prevention strategies. The direct thrombin inhibitor, dabigatran, was recently approved for prevention of stroke in patients with AF. The other drugs close to clinical approval include factor Xa inhibitors rivaroxaban and abixaban. According to the speaker, left atrial appendage closure may be a feasible alternative in patients with contraindication to OAC, in elderly patients with high bleeding risk and in post-ablation patients with high risk of stroke.
Dr. Mavrakis discussed the role of anticoagulation after AF ablation. According to the current Guidelines, it is recommended to use OAC for 2-3 months after ablation in all patients. Thereafter the need of OAC depends on the risk factors of stroke. Dr. Mavrakis concluded that OAC should not be stopped after ablation in patient with CHADS2 score ≥ 2. In conclusion, the session nicely summarized currently available data on antithrombotic policies in patients with AF and provided important practical hints how to improve management of specific patient populations.
Antithrombotic policies in atrial fibrillation patients
© 2017 European Society of Cardiology. All rights reserved